Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | Cancelled | |||
| Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | List with clinical criteria and/or conditions | Complete | ||
| Multaq | Dronedarone hydrochloride | Atrial fibrillation | Do not list | Complete | ||
| Dupixent | dupilumab | Atopic dermatitis, pediatrics | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cibinqo | abrocitinib | Atopic dermatitis, moderate to severe | Reimburse with clinical criteria and/or conditions | Complete | ||
| Adtralza | tralokinumab | atopic dermatitis (AD) | Active | |||
| Adtralza | tralokinumab | atopic dermatitis | Do not reimburse | Complete | ||
| TBC | lebrikizumab | atopic dermatitis | Active | |||
| Dupixent | dupilumab | atopic dermatitis | Do not reimburse | Complete | ||
| Eucrisa | crisaborole | atopic dermatitis | Do not reimburse | Complete |
Last Updated : April 27, 2024